Extended Data Fig. 2: Liver metastasis diminishes immunotherapy efficacy in mice.
From: Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination
a Schematic for establishing experimental liver metastasis by intrasplenic inoculation. b Schematic for establishing experimental liver tumours by intrahepatic inoculation. c Subcutaneous tumour growth in mice bearing liver tumours established by intrahepatic inoculation, with and without anti-PD-L1 therapy. Two-way ANOVA, mean ± SD, n = 6 per group. d Bioluminescent quantification of secondary tumour burden of a liver tumour from mouse bearing a subcutaneous tumour and liver tumour (as in Fig. 2i) versus the contralateral subcutaneous tumour in mice bearing two subcutaneous tumours (as in Fig. 2h) by bioluminescence. Quantification on day 7 prior to initiation of anti-PD-L1. Unpaired two-tailed Student’s t-test, mean ± SD, n = 10 per group. e, f Subcutaneous MC38 tumour volume (e) and weight (f) in mice with and without liver tumours in which a limited number (1×106) of tumour cells were inoculated subcutaneously. Weight analysed 4 weeks after tumour inoculation. (e) two-way ANOVA; (f) unpaired two-tailed Student’s t-test, mean ± SD, n = 5 per group. Data are representative of at least two independent experiments (c-f).
